Abstract
Background: The Reduction in ENdpoints with the Angiotensin Antagonist Losartan (RENAAL) study reported that losartan delayed the progression of renal disease in patients with type 2 diabetes and nephropathy. Diabetic or renally impaired patients are at high cardiovascular risk, a risk potentially increased in patients with both conditions.
Hypothesis: This post hoc analysis examined whether baseline proteinuria was predictive of cardiovascular outcomes, and whether losartan modifies the risk of cardiovascular outcomes in these patients given its renal‐protective effects.
Methods: The RENAAL study compared losartan with placebo (in addition to conventional antihypertensive medications) in type 2 diabetic patients with proteinuria. Morbidity and mortality due to cardiovascular causes were ascertained, and the relationship between baseline proteinuria and cardiovascular outcome was determined. The effect of treatment with losartan was examined using three time‐to‐event analyses of composite cardiorenal outcomes as described below.
Results: Increasing baseline proteinuria was associated with significantly increased risk of myocardial infarction (MI) and all‐cause or cardiovascular death, but not stroke. Losartan significantly reduced the risk for the combined endpoint of end‐stage renal disease (ESRD), MI, stroke, or death by 21% (p ≤ 0.005), irrespective of whether all‐cause or cardiovascular death was included in the analysis. In addition, losartan reduced the risk for the composite of ESRD or cardiovascular death by 19.2% (p < 0.05).
Conclusion: In patients with type 2 diabetes and nephropathy, there is an increased risk of MI and cardiovascular or all‐cause mortality. Treatment with losartan is associated with a reduction in proteinuria, a delay in the onset of ESRD, and no increased risk of cardiovascular events in this pre‐ESRD population.
Keywords: diabetes mellitus, myocardial infarction, stroke, mortality
Full Text
The Full Text of this article is available as a PDF (53.9 KB).
References
- 1. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. J Am Med Assoc 1999; 281: 1291–1297 [DOI] [PubMed] [Google Scholar]
- 2. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 1979; 241: 2035–2038 [DOI] [PubMed] [Google Scholar]
- 3. Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC: Serum albumin and risk of myocardial infarction and all‐cause mortality in the Framingham Offspring Study. Circulation 2002; 106: 2919–2924 [DOI] [PubMed] [Google Scholar]
- 4. Diercks GF, Hillege HL, van Boven AJ, Kors JA, Crijns HJ, Grobbee DE, de Jong PE, van Gilst WH: Microalbuminuria modifies the mortality risk associated with electrocardiographic ST‐T segment changes. J Am Coll Cardiol 2002; 40: 1401–1407 [DOI] [PubMed] [Google Scholar]
- 5. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777–1782 [DOI] [PubMed] [Google Scholar]
- 6. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kopecky SL, Jaffe AS: Acute myocardial infarction and renal dysfunction: A high‐risk combination. Ann Intern Med 2002; 137: 563–570 [DOI] [PubMed] [Google Scholar]
- 7. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A: Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218–225 [DOI] [PubMed] [Google Scholar]
- 8. Al‐Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 955–962 [DOI] [PubMed] [Google Scholar]
- 9. National Institutes of Health : US Renal Data System Report 2000, Section A, Incidence of Reported ESRD. 2000; 249–293
- 10. Herzog CA, Ma JZ, Collins AJ: Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002; 106: 2207–2211 [DOI] [PubMed] [Google Scholar]
- 11. Meyer KB, Levey AS: Controlling the epidemic of cardiovascular disease in chronic renal disease: Report from the National Kidney Foundation Task Force on cardiovascular disease. J Am Soc Nephrol 1998; 9: S31–S42 [PubMed] [Google Scholar]
- 12. Fuller JH, Stevens LK, Wang SL: Risk factors for cardiovascular mortality and morbidity: The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (suppl 2): S54–S64 [DOI] [PubMed] [Google Scholar]
- 13. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001; 286: 421–426 [DOI] [PubMed] [Google Scholar]
- 14. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869 [DOI] [PubMed] [Google Scholar]
- 15. Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simpson R, Shahinar S: The losartan renal protection study—rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Sys 2000; 1: 328–335 [DOI] [PubMed] [Google Scholar]
- 16. Anavekar NS, McMurray JJV, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285–1295 [DOI] [PubMed] [Google Scholar]
- 17. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C‐Y: Chronic kidney disease and the risks of death. Cardiovascular events and hospitalization. N Engl J Med 2004; 351: 1296–1305 [DOI] [PubMed] [Google Scholar]
- 18. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1–290 [PubMed] [Google Scholar]
- 19. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BN, Locatelli F, Goldhaber SZ, Lewis EJ: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138: 542–549 [DOI] [PubMed] [Google Scholar]
- 20. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators : Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO‐HOPE sub‐study. Lancet 2000; 355: 253–259 [PubMed] [Google Scholar]
- 21. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe‐Pedersen O, Neminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, for the LIFE Study Group : Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 1004–1010 [DOI] [PubMed] [Google Scholar]
- 22. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234 [DOI] [PubMed] [Google Scholar]